CoChat

Characterising metabolomic signatures of lipid-modifying therapies through drug target mendelian randomisation

Open access

Published version of a preprint

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

Large-scale molecular profiling and genotyping provide a unique opportunity to systematically compare the genetically predicted effects of therapeutic targets on the human metabolome. We firstly constructed genetic risk scores for 8 drug targets on the basis that they primarily modify low-density lipoprotein (LDL) cholesterol (HMGCR, PCKS9, and NPC1L1 ) , high-density lipoprotein (HDL) cholesterol (CETP), or triglycerides (APOC3, ANGPTL3, ANGPTL4, and LPL). Conducting mendelian randomisation (MR) provided strong evidence of an effect of drug-based genetic scores on coronary artery disease (CAD) risk with the exception of ANGPTL3. We then systematically estimated the effects of each score on 249 metabolic traits derived using blood samples from an unprecedented sample size of up to 115,082 UK Biobank participants. Genetically predicted effects were generally consistent among drug targets, which were intended to modify the same lipoprotein lipid trait. For example, the linear fit for the MR estimates on all 249 metabolic traits for genetically predicted inhibition of LDL cholesterol lowering targets HMGCR and PCSK9 was r 2 = 0.91. In contrast, comparisons between drug classes that were designed to modify discrete lipoprotein traits typically had very different effects on metabolic signatures (for instance, HMGCR versus each of the 4 triglyceride targets all had r 2 < 0.02). Furthermore, we highlight this discrepancy for specific metabolic traits, for example, finding that LDL cholesterol lowering therapies typically had a weak effect on glycoprotein acetyls, a marker of inflammation, whereas triglyceride modifying therapies assessed provided evidence of a strong effect on lowering levels of this inflammatory biomarker. Our findings indicate that genetically predicted perturbations of these drug targets on the blood metabolome can drastically differ, despite largely consistent effects on risk of CAD, with potential implications for biomarkers in clinical development and measuring treatment response.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pbio.3001547

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 A schematic representation of the drug-target MR approach undertaken in this study using, for instance, HMGCR variants to proxy for HMG-CoA reductase inhibition (the mechanism of action of statin therapy) to estimate its genetically predicted effect on CAD. Genetic variants robustly associated with a lipoprotein lipid trait (for instance, LDL cholesterol) based on P < 1 × 10−6 within 100 kbs of encoding genes were identified as genetic proxies for perturbing therapeutic targets. A sensitivity analysis restricted to 50 kbs on either side of encoding genes was also undertaken in this study. CAD, coronary artery disease; kbs, kilobases; LDL, low-density lipoprotein; MR, mendelian randomisation.
Fig 1 A schematic representation of the drug-target MR approach undertaken in this study using, for instance, HMGCR variants to proxy for HMG-CoA reductase inhibition (the mechanism of action of statin therapy) to estimate its genetically predicted effect on CAD. Genetic variants robustly associated with a lipoprotein lipid trait (for instance, LDL cholesterol) based on P < 1 × 10−6 within 100 kbs of encoding genes were identified as genetic proxies for perturbing therapeutic targets. A sensitivity analysis restricted to 50 kbs on either side of encoding genes was also undertaken in this study. CAD, coronary artery disease; kbs, kilobases; LDL, low-density lipoprotein; MR, mendelian randomisation.CC BY · PubMed Central
Fig 2 A forest plot visualising the genetically predicted effects of lipid-modifying drug targets on risk of CAD and T2D using MR. Estimates are colour coded based on the lipoprotein lipid trait estimates used to derive genetic scores. Each genetic score was oriented to mimic the putative effects of drug targets on lipoprotein traits, meaning that effect estimates correspond to relative odds of disease per 1 SD change in either lower LDL cholesterol, higher HDL cholesterol, or lower triglyceride levels via each specific drug target. Note that in the case of CETP, we are not ascribing causal effects to HDL cholesterol—rather, we are orientating CAD/T2D effect estimates corresponding to a genetically predicted increase in HDL cholesterol arising from pharmacological inhibition of CETP. The data underlying this figure can be found in S2 Table. CAD, coronary artery disease; CETP, cholesteryl ester transfer protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MR, mendelian randomisation; SD, standard deviation; T2D, type 2 diabetes.
Fig 2 A forest plot visualising the genetically predicted effects of lipid-modifying drug targets on risk of CAD and T2D using MR. Estimates are colour coded based on the lipoprotein lipid trait estimates used to derive genetic scores. Each genetic score was oriented to mimic the putative effects of drug targets on lipoprotein traits, meaning that effect estimates correspond to relative odds of disease per 1 SD change in either lower LDL cholesterol, higher HDL cholesterol, or lower triglyceride levels via each specific drug target. Note that in the case of CETP, we are not ascribing causal effects to HDL cholesterol—rather, we are orientating CAD/T2D effect estimates corresponding to a genetically predicted increase in HDL cholesterol arising from pharmacological inhibition of CETP. The data underlying this figure can be found in S2 Table. CAD, coronary artery disease; CETP, cholesteryl ester transfer protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MR, mendelian randomisation; SD, standard deviation; T2D, type 2 diabetes.CC BY · PubMed Central
Fig 3 Forest plots illustrating the genetically predicted effects of lipid-modifying drug targets on measures of circulating metabolite concentrations using NMR in the UKB study. Effect estimates are based on an SD change in the genetically predicted drug target scores oriented to reflect therapeutic intervention (i.e., lower LDL cholesterol, lower triglycerides, and higher HDL cholesterol). Scores were derived using genetic variants robustly associated which lipoprotein lipid traits (as indicated in each target’s legend) at each encoding gene’s region. The data underlying this figure can be found in S7–S14 Tables. CETP, cholesteryl ester transfer protein; HDL, high-density lipoprotein; IDL, intermediate density lipoprotein; LDL, low-density lipoprotein; NMR, nuclear magnetic resonance; SD, standard deviation; UKB, UK Biobank; VLDL, very low-density lipoprotein.
Fig 3 Forest plots illustrating the genetically predicted effects of lipid-modifying drug targets on measures of circulating metabolite concentrations using NMR in the UKB study. Effect estimates are based on an SD change in the genetically predicted drug target scores oriented to reflect therapeutic intervention (i.e., lower LDL cholesterol, lower triglycerides, and higher HDL cholesterol). Scores were derived using genetic variants robustly associated which lipoprotein lipid traits (as indicated in each target’s legend) at each encoding gene’s region. The data underlying this figure can be found in S7–S14 Tables. CETP, cholesteryl ester transfer protein; HDL, high-density lipoprotein; IDL, intermediate density lipoprotein; LDL, low-density lipoprotein; NMR, nuclear magnetic resonance; SD, standard deviation; UKB, UK Biobank; VLDL, very low-density lipoprotein.CC BY · PubMed Central
Fig 4 A comparison of distributions between genetically predicted drug target effects (A) PCSK9, (B) CETP, and (C) LPL on metabolic traits using NMR in the UKB study. In each figure estimates are compared with the results from the HMGCR score. Effect estimates were scaled in accordance with the corresponding effects of these genetically predicted drugs targets on risk of CAD, which is why axes vary between plots. Points are coloured based on subcategories of metabolic traits indicated in the figure legends. The data underlying this figure can be found in S7, S8, S10, and S14 Tables. CAD, coronary artery disease; CETP, cholesteryl ester transfer protein; HDL, high-density lipoprotein; IDL, intermediate density lipoprotein; LDL, low-density lipoprotein; NMR, nuclear magnetic resonance; SD, standard deviation; UKB, UK Biobank; VLDL, very low-density lipoprotein.
Fig 4 A comparison of distributions between genetically predicted drug target effects (A) PCSK9, (B) CETP, and (C) LPL on metabolic traits using NMR in the UKB study. In each figure estimates are compared with the results from the HMGCR score. Effect estimates were scaled in accordance with the corresponding effects of these genetically predicted drugs targets on risk of CAD, which is why axes vary between plots. Points are coloured based on subcategories of metabolic traits indicated in the figure legends. The data underlying this figure can be found in S7, S8, S10, and S14 Tables. CAD, coronary artery disease; CETP, cholesteryl ester transfer protein; HDL, high-density lipoprotein; IDL, intermediate density lipoprotein; LDL, low-density lipoprotein; NMR, nuclear magnetic resonance; SD, standard deviation; UKB, UK Biobank; VLDL, very low-density lipoprotein.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Research works printed but not linked: 1

  1. Mendes PFAPP Moura JMSP, 2020, New drugs coming up in the field of lipid control, e-Journal of Cardiology. Practice, 19

Metadata

Authors
Richardson, T. G., Leyden, G. M., Wang, Q., Bell, J. A., Elsworth, B., Davey Smith, G., & Holmes, M. V.
Affiliations
  • University of Bristol (GB)
  • University of Oxford (GB)
Corresponding author
Richardson, Tom G.
Venue
PLOS Biology
Published
2022-02-25
Volume
20
Issue
2
Pages
e3001547
ISSN
  • 1544-9173 (ISSN-L)
  • 1545-7885
OpenAlex
W4214506665
Cited by
304
References
51
Citations by year
2026: 52 · 2025: 103 · 2024: 95 · 2023: 41 · 2022: 12
FWCI
60.45
Type
journal article
Language
en
Open access
Locations
  • PLoS Biology (publishedVersion, cc-by)
  • medRxiv (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Bristol Research (University of Bristol) (publishedVersion, cc-by-nc)
  • Explore Bristol Research (publishedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • British Heart Foundation (FS/18/23/33512)
  • Medical Research Council (MC_UU_00011/1)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
Keywords
lipid therapy, Mendelian randomization, blood metabolome, coronary artery disease risk, LDL cholesterol lowering, triglyceride lowering, HMGCR, PCSK9, NPC1L1, cholesteryl ester transfer protein, apolipoprotein C-III, ANGPTL3, ANGPTL4, lipoprotein lipase, glycoprotein acetyls, inflammatory markers, metabolic phenotypes, treatment response biomarkers
MeSH terms
Proprotein Convertase 9, Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Cholesterol, Humans, Lipoproteins, Cholesterol, HDL, Cholesterol, LDL, Triglycerides, Mendelian Randomization Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.